Jean L Koff1, Jing-Xia Li1,2, Xinyan Zhang3, Jeffrey M Switchenko3, Christopher R Flowers1, Edmund K Waller1. 1. Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia. 2. Hematology, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. 3. Biostatistics and Bioinformatics, Winship Cancer Institute, Emory University, Atlanta, Georgia.
Abstract
BACKGROUND: Posttransplant lymphoproliferative disorder (PTLD) is a life-threatening complication of solid organ transplantation. Histologic heterogeneity and a lack of treatment standards have made evaluating clinical outcomes in specific patient populations difficult. This systematic literature review investigated the impact of the PTLD histologic subtype on survival in a large data set. METHODS: Case series were identified on PubMed with the search terms post-transplant lymphoproliferative disorder/disease, PTLD, and solid organ transplantation, with additional publications identified through reference lists. The patient characteristics, immunosuppressive regimen, treatment, survival, and follow-up time for 306 cases were extracted from 94 articles, and these cases were combined with 11 cases from Emory University Hospital. Patients with a recorded subtype were included in a Kaplan-Meier survival analysis (n = 234). Cox proportional hazards regression analyses identified predictors of overall survival (OS) for each subtype and B-cell subgroup. RESULTS: OS differed significantly between monomorphic T-cell neoplasms (median, 9 months) and polymorphic, monomorphic B-cell, and Hodgkin-type neoplasms, for which the median OS was not reached (P = .0001). Significant differences in OS among B subgroups were not detected, but there was a trend toward decreased survival for patients with Burkitt-type PTLD. Kidney transplantation and a reduction of immunosuppression were associated with increased OS for patients with B-cell neoplasms in a multivariate analysis. Immunosuppression with azathioprine was associated with decreased OS for patients with T-cell neoplasms, whereas radiotherapy was associated with improved OS for patients with that subtype. CONCLUSIONS: The histologic subtype represents an important prognostic factor in PTLD, with patients with T-cell neoplasms exhibiting very poor OS. Possibly lower survival for certain subsets of patients with B-cell PTLD should be explored further and suggests the need for subtype-specific therapies to improve outcomes. Cancer 2018;124:2327-36.
BACKGROUND:Posttransplant lymphoproliferative disorder (PTLD) is a life-threatening complication of solid organ transplantation. Histologic heterogeneity and a lack of treatment standards have made evaluating clinical outcomes in specific patient populations difficult. This systematic literature review investigated the impact of the PTLD histologic subtype on survival in a large data set. METHODS: Case series were identified on PubMed with the search terms post-transplant lymphoproliferative disorder/disease, PTLD, and solid organ transplantation, with additional publications identified through reference lists. The patient characteristics, immunosuppressive regimen, treatment, survival, and follow-up time for 306 cases were extracted from 94 articles, and these cases were combined with 11 cases from Emory University Hospital. Patients with a recorded subtype were included in a Kaplan-Meier survival analysis (n = 234). Cox proportional hazards regression analyses identified predictors of overall survival (OS) for each subtype and B-cell subgroup. RESULTS:OS differed significantly between monomorphic T-cell neoplasms (median, 9 months) and polymorphic, monomorphic B-cell, and Hodgkin-type neoplasms, for which the median OS was not reached (P = .0001). Significant differences in OS among B subgroups were not detected, but there was a trend toward decreased survival for patients with Burkitt-type PTLD. Kidney transplantation and a reduction of immunosuppression were associated with increased OS for patients with B-cell neoplasms in a multivariate analysis. Immunosuppression with azathioprine was associated with decreased OS for patients with T-cell neoplasms, whereas radiotherapy was associated with improved OS for patients with that subtype. CONCLUSIONS: The histologic subtype represents an important prognostic factor in PTLD, with patients with T-cell neoplasms exhibiting very poor OS. Possibly lower survival for certain subsets of patients with B-cell PTLD should be explored further and suggests the need for subtype-specific therapies to improve outcomes. Cancer 2018;124:2327-36.
Authors: S H K Oertel; E Verschuuren; P Reinke; K Zeidler; M Papp-Váry; N Babel; R U Trappe; S Jonas; M Hummel; I Anagnostopoulos; B Dörken; H B Riess Journal: Am J Transplant Date: 2005-12 Impact factor: 8.086
Authors: Rami T Bustami; Akinlolu O Ojo; Robert A Wolfe; Robert M Merion; William M Bennett; Suzanne V McDiarmid; Alan B Leichtman; Philip J Held; Friedrich K Port Journal: Am J Transplant Date: 2004-01 Impact factor: 8.086
Authors: S Bhatia; N K Ramsay; M Steinbuch; K E Dusenbery; R S Shapiro; D J Weisdorf; L L Robison; J S Miller; J P Neglia Journal: Blood Date: 1996-05-01 Impact factor: 22.113
Authors: Vikas R Dharnidharka; Marianna B Ruzinova; Chun-Cheng Chen; Priyanka Parameswaran; Harry O'Gorman; Charles W Goss; Hongjie Gu; Gregory A Storch; Kristine Wylie Journal: Cancer Med Date: 2019-01-29 Impact factor: 4.452